myelodysplastic syndromes (MDS) | Aplastic Anemia & MDS International Foundation

myelodysplastic syndromes (MDS)

David Jacobsohn, MD, ScM

Jacobsohn, David
Division Chief, Blood and Marrow Transplanation
Children's National

David Jacobsohn, MD, ScM is the Division Chief, Blood and Marrow Transplanation at Children's National Hospital in Washington, D.C.   Previously, he was at Children’s Memorial Hospital in Chicago, where he served as a member of the Stem Cell Transplant Program staff and as the Director of the Chronic Graft-versus-Host Disease Clinic. He has lectured widely on GvHD/BMT in Europe, Latin America, and the United States. Dr.

Myeloablative Conditioning for Allogeneic Transplantation Results in Superior Disease-Free Survival for Acute Myeloid Leukemia and Myelodysplastic Syndromes with Low/Intermediate, but not High Disease Risk Index: A CIBMTR Study: Superior DFS with MAC comp

Author(s): 
Bejanyan N, Zhang M, Bo-Subait K, Brunstein C, Wang H, Warlick ED, Giralt S, Nishihori T, Martino R, Passweg J, Dias A, Copelan E, Hale G, Gale RP, Solh M, Kharfan-Dabaja MA, Diaz MA, Ganguly S, Gore S, Verdonck LF, Hossain NM, Kekre N, Savani B, Byrne M
Primary Author: 
Bejanyan N
Journal Title: 
Biology of blood and marrow transplantation: journal of the American Society for Blood and Marrow Transplantation
Original Publication Date: 
Sep 2020

Myeloablative (MAC) as compared to reduced-intensity conditioning (RIC) is generally associated with lower relapse risk after allogeneic hematopoietic cell transplantation (HCT) for

Following in the footsteps of acute myeloid leukemia: are we witnessing the start of a therapeutic revolution for higher-risk myelodysplastic syndromes?

Author(s): 
Jan Philipp Bewersdorf, Amer M Zeidan
Primary Author: 
Jan Philipp
Journal Title: 
Leukemia & Lymphoma
Original Publication Date: 
Oct 2020

For most patients with higher-risk

Bone Marrow Diseases: 

The IPSS-R more accurately captures fatigue severity of newly diagnosed patients with myelodysplastic syndromes compared with the IPSS index

Author(s): 
Efficace F, Cottone F, Oswald LB, Cella D, Patriarca A, Niscola P, Breccia M, Platzbecker U, Palumbo GA, Caocci G, Stauder R, Ricco A, Petranovic D, Caers J, Luppi M, Fianchi L, Frairia C, Capodanno I, Follini E, Sarlo C, Fazi P, Vignetti M
Primary Author: 
Efficace F
Journal Title: 
Leukemia
Original Publication Date: 
Sep 2020

We aimed to compare fatigue of newly diagnosed patients with

Bone Marrow Diseases: 

Machine learning demonstrates that somatic mutations imprint invariant morphologic features in myelodysplastic syndromes

Author(s): 
Nagata Y, Zhao R, Awada H, Kerr CM, Mirzaev I, Kongkiatkamon S, Nazha A, Makishima H, Radivoyevitch T, Scott JG, Sekeres MA, Hobbs BP, Maciejewski JP
Primary Author: 
Nagata Y
Journal Title: 
Blood
Original Publication Date: 
Sep 2020

Morphological interpretation is the standard in diagnosing myelodysplastic syndrome (MDS), but it has limitations, such as varying reliability in pathologic evaluation and lack of integration with genetic data. Somatic events shape morphologic features, but the complexity of morphologic and genetic changes make clear associations challenging. This article interrogates novel clinical subtypes of MDS using a machine learning technique devised to identify patterns of co-occurrence among morphologic features and genomic events.

Bone Marrow Diseases: 

Management of higher risk myelodysplastic syndromes after hypomethylating agents failure: are we about to exit the black hole?

Author(s): 
Bewersdorf JP, Zeidan AM
Primary Author: 
Bewersdorf JP
Journal Title: 
Expert Review of Hematology
Original Publication Date: 
Sep 2020

Introduction: Hypomethylating agents (HMA) remain the mainstay of treatment for patients with higher-risk

Bone Marrow Diseases: